List PLR Content Marketing Belize

Thursday, October 27, 2016

Bystolic

Bystolic is a brand name of nebivolol, approved by the FDA in the following formulation(s):

BYSTOLIC (nebivolol hydrochloride - tablet; oral)

Manufacturer: FOREST LABS

Approval date: December 17, 2007

Strength(s): EQ 10MG BASE, EQ 2.5MG BASE, EQ 5MG BASE

Manufacturer: FOREST LABS

Approval date: October 8, 2008

Strength(s): EQ 20MG BASE ^[RLD]

Has a generic version of Bystolic been approved?

No. There is currently no therapeutically equivalent version of Bystolic available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bystolic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Compositions containing micronized nebivolol
Patent 5,759,580
Issued: June 2, 1998
Inventor(s): Jans; Eugeen Marie Jozef & Smans; Guido Franciscus & Gilis; Paul Marie Victor
Assignee(s): Janssen Pharmaceutica, N.V.
The present invention relates to pharmaceutical compositions containing as active ingredient micronized nebivolol of formula (I) and ways of preparing said compositions. ##STR1##
Patent expiration dates:
- June 2, 2015
  ✓
  Drug product

Method of lowering the blood pressure
Patent 6,545,040
Issued: April 8, 2003
Inventor(s): Raymond Mathieu; Xhonneux & Guy Rosalia Eugène; Van Lommen
Assignee(s): Janssen Pharmaceutica N.V.
A method of potentiating the effects of blood pressure reducing agents in warm-blooded animals, said method comprising administering to said warm-blooded animals of an effective amount of a blood pressure reducing agent and a 2,2′-iminobisethanol derivative.
Patent expiration dates:
- December 17, 2021
  ✓
  Patent use: TREATMENT OF HYPERTENSION
  ✓
  Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- December 17, 2012 - NEW CHEMICAL ENTITY

Has a generic version of Brovana been approved?

No. There is currently no therapeutically equivalent version of Brovana available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brovana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
Patent 5,795,564
Issued: August 18, 1998
Inventor(s): Aberg; Gunnar & Morley; John
Assignee(s): Sepracor, Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased bronchial distribution when administered by inhalation.
Patent expiration dates:
- April 3, 2012
  ✓
  Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

Formoterol process
Patent 6,040,344
Issued: March 21, 2000
Inventor(s): Gao; Yun & Hett; Robert & Fang; Kevin Q. & Wald; Stephen A. & Redmon; Martin P. & Senanayake; Chris Hugh
Assignee(s): Sepracor Inc.
A method is disclosed for the preparation of optically pure isomers of formoterol by the reaction of an optically pure 4-benzyloxy-3-formamidostyrene oxide with an optically pure 4-methoxy-.alpha.-methyl-N-(phenylmethyl)benzeneethanamine followed by debenzylation. Useful intermediates in the process are also disclosed, as are the novel L-tartrate salt of R,R-formoterol and pharmaceutical compositions thereof.
Patent expiration dates:
- November 12, 2016
  ✓
  Drug substance

Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
Patent 6,068,833
Issued: May 30, 2000
Inventor(s): Aberg; Gunnar & Morley; John
Assignee(s): Sepracor Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.
Patent expiration dates:
- April 3, 2012
  ✓
  Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

Formoterol tartrate process and polymorph
Patent 6,472,563
Issued: October 29, 2002
Inventor(s): Gerald J.; Tanoury & Chris H.; Senanayake & Donald W; Kessler
Assignee(s): Sepracor Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
Patent expiration dates:
- November 9, 2021
  ✓
  Drug substance

Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
Patent 6,589,508
Issued: July 8, 2003
Inventor(s): Gunnar; Aberg & John; Morley
Assignee(s): Sepracor Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.
Patent expiration dates:
- April 3, 2012
  ✓
  Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

Formoterol tartrate polymorph
Patent 6,720,453
Issued: April 13, 2004
Inventor(s): Gerald J.; Tanoury & Chris H.; Senanayake & Donald W; Kessler
Assignee(s): Sepracor Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
Patent expiration dates:
- November 9, 2021
  ✓
  Drug substance

Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
Patent 6,866,839
Issued: March 15, 2005
Inventor(s): Aberg; Gunnar & Morley; John
Assignee(s): Sepracor Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.
Patent expiration dates:
- April 3, 2012
  ✓
  Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

Formoterol tartrate polymorph
Patent 7,145,036
Issued: December 5, 2006
Inventor(s): Tanoury; Gerald J. & Senanayake; Chris H. & Kessler; Donald W.
Assignee(s): Sepracor Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
Patent expiration dates:
- November 9, 2021
  ✓
  Drug substance

Formoterol tartrate process and polymorph
Patent 8,110,706
Issued: February 7, 2012
Inventor(s): Tanoury; Gerald J. & Senanayake; Chris H. & Kessler; Donald W.
Assignee(s): Sunovion Pharmaceuticals Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
Patent expiration dates:
- November 9, 2021
  ✓
  Drug product

Has a generic version of Fragmin been approved?

No. There is currently no therapeutically equivalent version of Fragmin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fragmin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Fragmin.

Has a generic version of Fosamax been approved?

A generic version of Fosamax has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Fosamax and have been approved by the FDA:

alendronate sodium tablet; oral

Manufacturer: APOTEX

Approval date: August 4, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: AUROBINDO PHARMA

Approval date: August 4, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: AUSTARPHARMA LLC

Approval date: September 24, 2009

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: CADISTA PHARMS

Approval date: February 18, 2010

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: DR REDDYS LABS LTD

Approval date: August 4, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: August 4, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: SUN PHARMA GLOBAL

Approval date: September 10, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: TEVA PHARMS

Approval date: February 6, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 40MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: August 4, 2008

Strength(s): EQ 10MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 35MG BASE ^[AB], EQ 40MG BASE ^[AB], EQ 40MG BASE ^[AB], EQ 5MG BASE ^[AB], EQ 70MG BASE ^[AB], EQ 70MG BASE ^[AB]

Note: No generic formulation of the following product is available.

alendronate sodium - solution; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fosamax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Dry mix formulation for bisphosphonic acids with lactose
Patent 5,358,941
Issued: October 25, 1994
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
Patent expiration dates:
- December 2, 2012
- June 2, 2013
  ✓
  Pediatric exclusivity

Oral liquid alendronate formulations
Patent 5,462,932
Issued: October 31, 1995
Inventor(s): Brenner; Gerald S. & Katdare; Ashok V. & Pretzer; Denise & Whiteford; Donna T.
Assignee(s): Merck & Co., Inc.
Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.
Patent expiration dates:
- May 17, 2014
- November 17, 2014
  ✓
  Pediatric exclusivity

Dry mix formulation for bisphosphonic acids
Patent 5,681,590
Issued: October 28, 1997
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
Patent expiration dates:
- December 2, 2012
- June 2, 2013
  ✓
  Pediatric exclusivity

Method for inhibiting bone resorption
Patent 5,994,329
Issued: November 30, 1999
Inventor(s): Daifotis; Anastasia G. & Santora, II; Arthur C. & Yates; A. John
Assignee(s): Merck & Co., Inc.
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
Patent expiration dates:
- July 17, 2018
  ✓
  Sponsor has requested patent be delisted
- January 17, 2019
  ✓
  Pediatric exclusivity

Method for inhibiting bone resorption
Patent 6,015,801
Issued: January 18, 2000
Inventor(s): Daifotis; Anastasia G. & Yates; A. John & Santora, II; Arthur C.
Assignee(s): Merck & Co., Inc.
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for caring out the therapeutic methods disclosed herein.
Patent expiration dates:
- July 17, 2018
  ✓
  Sponsor has requested patent be delisted
- January 17, 2019
  ✓
  Pediatric exclusivity

Dry mix formulation for bisphosphonic acids
Patent 6,090,410
Issued: July 18, 2000
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
Patent expiration dates:
- December 2, 2012
- June 2, 2013
  ✓
  Pediatric exclusivity

Dry mix formulation for bisphosphonic acids
Patent 6,194,004
Issued: February 27, 2001
Inventor(s): Bechard; Simon R. & Kramer; Kenneth A. & Katdare; Ashok V.
Assignee(s): Merck & Co., Inc.
Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.
Patent expiration dates:
- December 2, 2012
- June 2, 2013
  ✓
  Pediatric exclusivity

Method for inhibiting bone resorption
Patent 6,225,294
Issued: May 1, 2001
Inventor(s): Daifotis; Anastasia G. & Santora, II; Arthur C. & Yates; A. John
Assignee(s): Merck & Co., Inc.
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.
Patent expiration dates:
- July 17, 2018
  ✓
  Sponsor has requested patent be delisted
- January 17, 2019
  ✓
  Pediatric exclusivity

Has a generic version of Renova been approved?

A generic version of Renova has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Renova and have been approved by the FDA:

tretinoin cream; topical

Manufacturer: SPEAR PHARMS

Approval date: September 15, 2005

Strength(s): 0.05% ^[AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Renova. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Oil-in-water emulsion containing tretinoin
Patent 6,531,141
Issued: March 11, 2003
Inventor(s): John; Marvel
Assignee(s): Ortho-McNeil Pharmaceutical, Inc.
The present invention relates to an oil-in-water emulsion containing tretinoin and the use thereof in mitigating skin disorders such as acne, photodamaged skin, wrinkles, mottled hyperpigmentation, tactile roughness, and yellowing of facial skin.
Patent expiration dates:
- March 7, 2020

Has a generic version of Cardizem LA been approved?

A generic version of Cardizem LA has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Cardizem LA and have been approved by the FDA:

diltiazem hydrochloride tablet, extended release; oral

Manufacturer: WATSON LABS FLORIDA

Approval date: March 15, 2010

Strength(s): 120MG ^[AB], 180MG ^[AB], 240MG ^[AB], 300MG ^[AB], 360MG ^[AB], 420MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cardizem LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Extended release form of diltiazem
Patent 5,529,791
Issued: June 25, 1996
Inventor(s): Deboeck; Arthur M. & Baudier; Philippe R.
Assignee(s): Galephar P.R., Inc., Ltd.
An extended-release galenical form of Diltiazem or a pharmaceutically acceptable salt thereof, which comprises beads containing said Diltiazem or a pharmaceutically acceptable salt thereof as an active ingredient and a wetting agent, said beads being coated with a microporous membrane comprising at least a water-soluble or water-dispersible polymer or copolymer and a pharmaceutically acceptable adjuvant.
Patent expiration dates:
- June 25, 2013

Cushioning wax beads for making solid shaped articles
Patent 6,923,984
Issued: August 2, 2005
Inventor(s): Remon; Jean Paul
Assignee(s): Universiteit Gent
Biologically inactive cushioning beads comprise at least one compressible cushioning component consisting essentially of a microcrystalline hydrocarbon wax or a natural wax, the said wax being at least 30% by weight of the biologically inactive cushioning beads. Such beads are useful for making solid shaped articles containing biologically active ingredients by compression.
Patent expiration dates:
- February 25, 2021
  ✓
  Drug product

Chronotherapeutic diltiazem formulations and the administration thereof
Patent 7,108,866
Issued: September 19, 2006
Inventor(s): Albert; Kenneth Stephen & Maes; Paul José
Assignee(s): Biovall Laboratories International SRL
A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 15 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.
Patent expiration dates:
- December 17, 2019
  ✓
  Patent use: TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
  ✓
  Drug product

Has a generic version of Zanaflex been approved?

A generic version of Zanaflex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zanaflex and have been approved by the FDA:

tizanidine hydrochloride capsule; oral

Manufacturer: APOTEX INC

Approval date: February 3, 2012

Strength(s): EQ 2MG BASE ^[AB], EQ 4MG BASE ^[AB], EQ 6MG BASE ^[AB]

tizanidine hydrochloride tablet; oral

Manufacturer: ALPHAPHARM

Approval date: December 16, 2003

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: APOTEX

Approval date: January 16, 2004

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: CARACO

Approval date: September 29, 2003

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: COREPHARMA

Approval date: October 11, 2002

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: DR REDDYS LABS INC

Approval date: July 3, 2002

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: March 28, 2003

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: SANDOZ

Approval date: June 27, 2002

Strength(s): EQ 4MG BASE ^[AB]

Manufacturer: TEVA

Approval date: July 3, 2002

Strength(s): EQ 4MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zanaflex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method of reducing somnolence in patients treated with tizanidine
Patent 6,455,557
Issued: September 24, 2002
Inventor(s): Cara A.; Pellegrini & Paul; Stark
Assignee(s): Elan Pharmaceuticals, Inc.
An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.
Patent expiration dates:
- November 28, 2021

Thursday, October 27, 2016

BYSTOLIC (nebivolol hydrochloride - tablet; oral)

Has a generic version of Bystolic been approved?

Related Patents

Related Exclusivities

See also...

BROVANA (arformoterol tartrate - solution; inhalation)

Has a generic version of Brovana been approved?

Related Patents

See also...

FRAGMIN (dalteparin sodium - injectable; subcutaneous)

Has a generic version of Fragmin been approved?

Related Patents

See also...

FOSAMAX (alendronate sodium - solution; oral)

FOSAMAX (alendronate sodium - tablet; oral)

Has a generic version of Fosamax been approved?

alendronate sodium tablet; oral

Related Patents

See also...

RENOVA (tretinoin - cream; topical)

Has a generic version of Renova been approved?

tretinoin cream; topical

Related Patents

See also...

CARDIZEM LA (diltiazem hydrochloride - tablet, extended release; oral)

Has a generic version of Cardizem LA been approved?

diltiazem hydrochloride tablet, extended release; oral

Related Patents

See also...

ZANAFLEX (tizanidine hydrochloride - capsule; oral)

ZANAFLEX (tizanidine hydrochloride - tablet; oral)

Has a generic version of Zanaflex been approved?

tizanidine hydrochloride capsule; oral

tizanidine hydrochloride tablet; oral

Related Patents

See also...